NOVN.VX - Novartis AG

Swiss - Swiss Delayed price. Currency in CHF
94.26
+0.06 (+0.06%)
As of 5:31PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close94.20
Open94.18
Bid93.88 x 373700
Ask94.00 x 1281100
Day's range93.64 - 94.52
52-week range72.96 - 94.52
Volume4,409,416
Avg. volume3,278,602
Market cap240.421B
Beta (3Y monthly)N/A
PE ratio (TTM)27.63
EPS (TTM)N/A
Earnings date23 Jan 2018 - 29 Jan 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est88.59
  • Powell Just One Global Central Banker Under Political Pressure
    Bloomberg8 hours ago

    Powell Just One Global Central Banker Under Political Pressure

    The independence that monetary policy makers have traditionally enjoyed from politicians is under threat worldwide as much as it is in the U.S., where Powell repeatedly runs into tweeted attacks from President Donald Trump. Central banks from Turkey to India are regularly under pressure and even the Bank of England and European Central Bank aren’t immune to attacks from elected critics.

  • Switzerland Votes ‘Yes’ to Being Tax Home for Big Business
    Bloomberg4 days ago

    Switzerland Votes ‘Yes’ to Being Tax Home for Big Business

    Switzerland approved an overhaul of the corporate tax code, choosing to stay an attractive base for companies like Procter & Gamble, Vitol SA and Caterpillar Inc. even at the expense of a short-term drop in fiscal revenue. The outcome, approved by 66.4% of voters, ends years of wrangling and a failed attempt at an overhaul two years ago, ensures Switzerland remains a low tax domicile for companies and still is compliant with international rules.

  • The World’s Rich Once Flocked to Geneva. Now Its Allure May Be Fading
    Bloomberg7 days ago

    The World’s Rich Once Flocked to Geneva. Now Its Allure May Be Fading

    The property is a reminder of a time when millionaires parking money in clandestine accounts made a beeline for Geneva. Although the city has largely recovered from the end of secrecy at banks, whose numbers have shrunk by a quarter, Geneva faces questions about its allure for international businesses and the world’s wealthy. It wasn’t the city of choice for the likes of Netflix Inc., Alibaba Group Holding Ltd. and Amazon.com Inc. to base their European operations. The city, surrounded by the Alps and the Jura mountains and with a view of Mont Blanc, still has its resplendent landmark hotels, but they don’t get the fillip they once did from rich Arab guests each summer. “Sometimes I have the sense that we’re not hungry enough,” said Thierry Lavalley, general manager of the lake-facing Grand Hotel Kempinski Geneve.

  • Do Novartis's (VTX:NOVN) Earnings Warrant Your Attention?
    Simply Wall St.9 days ago

    Do Novartis's (VTX:NOVN) Earnings Warrant Your Attention?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Bloomberg28 days ago

    How to Prevent Shortages of Life-Saving Drugs

    Erin Fox, director of the drug information service at the University of Utah, said that this is a stubborn problem. Last year, then-FDA commissioner Scott Gottlieb proposed a move to approve more suppliers, but even with lower barriers to entry, it might not make economic sense for companies to build an expensive factory, or revamp a crumbling one, to make very cheap drugs with a minuscule profit margin. As this Bloomberg Opinion column from last year concludes: There’s good reason hospitals were not in the drug business.

  • What Do Analysts Think About Novartis AG's (VTX:NOVN) Growth?
    Simply Wall St.last month

    What Do Analysts Think About Novartis AG's (VTX:NOVN) Growth?

    Based on Novartis AG's (VTX:NOVN) earnings update in December 2018, analyst consensus outlook appear pessimistic, with profits p...

  • Why Novartis AG (VTX:NOVN) Could Have A Place In Your Portfolio
    Simply Wall St.2 months ago

    Why Novartis AG (VTX:NOVN) Could Have A Place In Your Portfolio

    Attractive stocks have exceptional fundamentals. In the case of Novartis AG (VTX:NOVN), there's is a highly-regarded dividend-paying company with a a great track record of delivering benchmark-beating performance. In theRead More...

  • Is Novartis AG’s (VTX:NOVN) P/E Ratio Really That Good?
    Simply Wall St.3 months ago

    Is Novartis AG’s (VTX:NOVN) P/E Ratio Really That Good?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! This article is for investors who would like to improveRead More...

  • Reuters3 months ago

    Clinigen agrees to buy U.S. rights to Novartis' cancer drug Proleukin

    (Reuters) - British pharmaceutical firm Clinigen Group Plc said on Wednesday it had agreed to acquire the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin for a total of ...

  • Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript

    LGND earnings call for the period ending December 31, 2018.

  • Reuters3 months ago

    Novartis CEO lauds Trump administration plan to overhaul rebates

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines..

  • Novartis CEO says U.S. rebate plan will return cash to patients
    Reuters3 months ago

    Novartis CEO says U.S. rebate plan will return cash to patients

    Novartis AG Chief Executive Vas Narasimhan said his company's prescription drug prices have been "flat to negative" over the last three years, and directed blame for high costs for U.S. patients on industry middlemen that manage drug benefits. In an interview with Reuters in New York on Wednesday Narasimhan, a 42-year-old U.S. doctor who has headed the Swiss drugmaker since Feb. 2018, threw his support behind a U.S. government proposal to end a system of rebates drugmakers pay to pharmacy benefit managers (PBMs) and health insurers in order to get products on their lists of covered medicines.

  • Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript

    ARRY earnings call for the period ending December 31, 2018.

  • Novartis's Alcon eye-care unit to enter Swiss index after spin off
    Reuters4 months ago

    Novartis's Alcon eye-care unit to enter Swiss index after spin off

    Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday. Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said. Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.

  • Reuters - UK Focus4 months ago

    LIVE MARKETS-Closing snapshots: Luxury, Serenity and Pleasure

    * European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Apple, Boeing lift Wall Street ahead of Fed decision Jan 30 - Welcome to the home for real-time coverage of European ...

  • Reuters4 months ago

    Novartis CEO sees 'further conversation' on Sandoz future in 18 months

    Novartis Chief Executive Vas Narasimhan said he will be ready to discuss the future of generics unit Sandoz following a revamp due to take 18 months, while still calling the business "an integral part" of the Swiss drugmaker. "We consider Sandoz an integral part of Novartis, we're focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis," Narasimhan said on a call with analysts on Wednesday.

  • Novartis 2019 growth outlook leaves investors wanting more
    Reuters4 months ago

    Novartis 2019 growth outlook leaves investors wanting more

    Novartis's 2019 sales and profit growth guidance disappointed investors seeking more from Chief Executive Vas Narasimhan's efforts to focus the Swiss drugmaker on high-tech medicines while shedding non-core assets. The company sees net sales growing by a low- to mid-single-digit percentage, with core operating income up by a mid-single-digit rate, Novartis said on Wednesday. Shares in the world's biggest prescription drugmaker had slipped 1.1 percent by 1305 GMT, lagging a 0.2 percent decline in the Stoxx European Health Care Index.

  • Reuters - UK Focus4 months ago

    LIVE MARKETS-Got legs?

    * European stocks inch up as trade talks loom * LVMH jumps, driving luxury stocks up * Lonza tumbles after sales miss, CEO retiring * Atos leads STOXX 600 after results Jan 30 - Welcome to the home for ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes